A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer.

MLA

Miyoshi, Yasuhide, et al. “A Novel Prediction Model for the Completion of Six Cycles of Radium-223 Treatment and Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.” World Journal of Urology, vol. 39, no. 9, Sept. 2021, pp. 3323–28. EBSCOhost, https://doi.org/10.1007/s00345-021-03639-z.

APA

Miyoshi, Y., Tsutsumi, S., Yasui, M., Kawahara, T., Uemura, K., Hayashi, N., Nozawa, M., Yoshimura, K., Uemura, H., & Uemura, H. (2021). A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer. World Journal of Urology, 39(9), 3323–3328. https://doi.org/10.1007/s00345-021-03639-z

Chicago

Miyoshi, Yasuhide, Sohgo Tsutsumi, Masato Yasui, Takashi Kawahara, Ko-ichi Uemura, Naruhiko Hayashi, Masahiro Nozawa, Kazuhiro Yoshimura, Hiroji Uemura, and Hirotsugu Uemura. 2021. “A Novel Prediction Model for the Completion of Six Cycles of Radium-223 Treatment and Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.” World Journal of Urology 39 (9): 3323–28. doi:10.1007/s00345-021-03639-z.